Suprasellar hemangioblastoma during pregnancy: illustrative case Authors: Patrick Toyota, Michael McKenzie, Jason R. Shewchuk, Ryojo Akagami, Peter Gooderham, Stephen Yip, Peter W. Schutz Published: 2026 ABSTRACT BACKGROUNDHemangioblastoma is a benign tumor that typically occurs in the posterior fossa but may be found anywhere along the neuroaxis. Its growth behavior may be difficult to predict, and pregnancy has been discussed as a possible growth-promoting factor.OBSERVATIONSThe authors report the case of a rare suprasellar apparently sporadic hemangioblastoma diagnosed during pregnancy. Following the progressive worsening of symptoms, the baby was delivered by cesarean section. The patient was treated with stereotactic radiotherapy, resulting in a marked improvement in symptoms and impressive reduction in tumor size.LESSONSHigh vascularity and solid growth with a tendency for surgical complications appear to be typical of suprasellar hemangioblastoma, as indicated by this and several other reported cases. The importance of nonsurgical treatment strategies, including radiation therapy, is emphasized by this case. Pregnancy is one of the factors that has been investigated as potentially growth promoting. The authors speculate that postpartum hormonal changes may have contributed to tumor shrinkage in their case. https://thejns.org/doi/10.3171/CASE26756 Hemangioblastoma is a highly vascular tumor composed of neoplastic stromal cells within a dense capillary network. It occurs sporadically in approximately 70% of cases; the other 30% occur as part of von Hippel–Lindau (VHL) disease.1 Hemangioblastoma can occur anywhere along the neuroaxis or the peripheral nervous system; however, the vast majority occur either in the posterior fossa or along the spinal cord. Stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT) are frequently used for the treatment of intracranial hemangioblastoma, although publications assessing the long-term clinical outcomes are lacking. Pregnancy is a possible promoter of hemangioblastoma growth and has been investigated in recent years.2,3 We present the case of a 30-year-old pregnant woman with a hemangioblastoma of the suprasellar region managed with SRT following delivery. This case illustrates unique phenomena that may be associated with hemangioblastoma arising in pregnancy. Illustrative Case A 30-year-old G1P0 female presented at 35 weeks’ gestation with a 1-month history of gradually progressive bitemporal hemianopsia, headache, impulsiveness, and short-term memory decline. She had a 10-year history of secondary amenorrhea, not previously investigated by imaging. Given her desire to get pregnant, she was placed on a gonadotropin-releasing hormone (GnRH) pulsatile pump to mimic the natural cycle and achieved ovulation pregnancy soon after initiation. Hypothyroidism had been diagnosed early in the pregnancy and was treated by hormone replacement. Her family history was negative for neoplastic disease. MRI showed a solid, 3.3 × 3.0 × 3.5–cm lesion in the suprasellar region with multiple flow voids on T2-weighted imaging (Fig. 1A). Postgadolinium T1-weighted imaging demonstrated avid enhancement of the mass (Fig. 1B). Adjacent edema extended through white matter tracts of both basal ganglia and throughout the deep and subcortical white matter of the posterior temporal lobes bilaterally. FIG. 1.A:Sagittal T2-weighted MR image obtained at presentation showing a solid, 3.3 × 3.0 × 3.5–cm lesion in the suprasellar region with multiple flow voids. B: Postgadolinium coronal T1-weighted MR image obtained at presentation demonstrating avid enhancement of the mass. C:Postgadolinium coronal T1-weighted MR image obtained 3 months after RT showing a significantly reduced tumor size, 2.1 × 1.9 × 2.1 cm. D:Postgadolinium coronal T1-weighted MR image obtained 5 years after treatment showing a residual tumor measuring 1.6 × 1.5 × 1.4 cm. E: Postgadolinium coronal T1-weighted MR image obtained 11 years after treatment showing a residual tumor measuring 1.4 × 1.4 × 1.4 cm. A:Sagittal T2-weighted MR image obtained at presentation showing a solid, 3.3 × 3.0 × 3.5–cm lesion in the suprasellar region with multiple flow voids. B: Postgadolinium coronal T1-weighted MR image obtained at presentation demonstrating avid enhancement of the mass. C:Postgadolinium coronal T1-weighted MR image obtained 3 months after RT showing a significantly reduced tumor size, 2.1 × 1.9 × 2.1 cm. D:Postgadolinium coronal T1-weighted MR image obtained 5 years after treatment showing a residual tumor measuring 1.6 × 1.5 × 1.4 cm. E: Postgadolinium coronal T1-weighted MR image obtained 11 years after treatment showing a residual tumor measuring 1.4 × 1.4 × 1.4 cm. The patient was admitted to the hospital for investigation, and within days, her vision deteriorated to only light perception in the right eye and counting fingers in the left. She also developed diabetes insipidus. Because of her rapidly progressive symptoms, the baby was delivered prior to neurosurgical intervention. A cesarean section was performed as the baby was in the breech position. The baby girl was within normal weight and had an Apgar score of 10 at 5 minutes of life. Preoperative hemoglobin and hematocrit levels were within the reference range for a third-trimester pregnancy, and no coagulopathic abnormalities were identified. An endoscopic endonasal approach was considered, but the limited proximal vascular control provided by the endonasal corridor was felt to be suboptimal given the tumor’s marked vascularity suggested by the preoperative imaging. A pterional approach was similarly considered unfavorable in this case, offering limited access to the contralateral side, which was felt to be relevant given the bihemispheric extension. The patient underwent bifrontal craniotomy and bilateral orbital osteotomy for attempted resection of the lesion. Intraoperatively, a bluish mass was visualized immediately deep to the lamina terminalis in the third ventricle. Because of excessive bleeding from the tumor, resection was abandoned, and the procedure was limited to a biopsy. The biopsy specimen showed a low-grade clear cell tumor consistent with hemangioblastoma. A prominent network of capillaries with interceding neoplastic stromal cells with vacuolated to clear cytoplasm was present (Fig. 2A). Capillaries were outlined by the endothelial marker CD34 (Fig. 2B), and stromal cells stained positively for inhibin A (Fig. 2C), S100, and EGFR, but were negative for IDH1 R132H, CD10, and EMA. There was no necrosis present, and the mitotic index and Ki-67 labeling index were low. FIG. 2.Biopsy of tumor demonstrating hemangioblastoma. A: H&E stain showing stromal cells with vacuolated cytoplasm and a dense capillary network. Original magnification ×40. B: CD34 immunohistochemical analysis with hematoxylin counterstain highlighting endothelial cells and the capillary network. Original magnification ×10. C:Inhibin immunohistochemical analysis with hematoxylin counterstain showingpositive stromal cells. Original magnification ×40. Biopsy of tumor demonstrating hemangioblastoma. A: H&E stain showing stromal cells with vacuolated cytoplasm and a dense capillary network. Original magnification ×40. B: CD34 immunohistochemical analysis with hematoxylin counterstain highlighting endothelial cells and the capillary network. Original magnification ×10. C:Inhibin immunohistochemical analysis with hematoxylin counterstain showingpositive stromal cells. Original magnification ×40. Immediately after surgery, her vision was worse, with no light perception in either eye. Her other symptoms were unchanged. Her vision improved slightly in the postoperative period. Screening by abdominal CT and ophthalmological examination did not indicate any VHL disease–related renal, adrenal, pancreatic, or retinal lesions. Neoadjuvant embolization of the tumor was not felt to be an option because the main tumor vessels derived directly from the internal carotid arteries, and further resection was believed to be unfeasible. The patient was treated with SRT for residual tumor to a total dose of 5400 cGy, given in 1.8-Gy fractions over 6 weeks. Six months after her initial presentation, and 3 months following the completion of SRT, the patient’s vision had returned to normal. At presentation, a Mini-Mental Status Examination revealed significant deficits in memory and concentration; however, at 5 months post-SRT, detailed neuropsychological assessments revealed only very subtle deficits, suggesting considerable improvements in cognition. Nine months post-SRT, the diabetes insipidus had resolved. However, the patient developed panhypopituitarism and was started on hormone replacement. At subsequent 6-monthly follow-ups, the patient continued to show gradual improvement in cognition. At 5 years post-SRT, the patient had near-normal cognition and was functioning well on hormone replacement for continued hypopituitarism. At 11 years post-SRT, the patient had stable vision and was back working full-time. At presentation, MRI showed the tumor dimensions to be 3.3 × 3.0 × 3.5 cm. At 3 months post-SRT, these dimensions had decreased to 2.1 × 1.9 × 2.1 cm (Fig. 1C); at 7 months post-SRT, the dimensions were measured at 1.7 × 1.7 × 1.7 cm, with significantly reduced peritumoral edema but no changes in enhancement or the presence of flow voids. Subsequent yearly MRI studies have demonstrated tumor stability with mild reduction in size. Five years after the conclusion of her course of radiotherapy, the patient’s MRI study showed a residual suprasellar lesion measured at 1.6 × 1.5 × 1.4 cm (Fig. 1D), and at the last follow-up, 11 years post-SRT, an MRI study showed no change in the size of the lesion (Fig. 1E). Informed Consent The necessary informed consent was obtained in this study. Discussion Observations Hemangioblastomas are benign, highly vascular lesions that can be either sporadic or associated with VHL disease. Approximately 30% are associated with VHL disease.1 Only 2.1%–2.9% of all hemangioblastomas are supratentorial.4 Suprasellar hemangioblastomas are exceedingly rare, and most cases in the literature are associated with VHL disease.5–7 No reported cases to date have presented during pregnancy. Like the present case, most demonstrate solid, often large, highly vascularized tumors that show prominent flow voids on MRI. Hemorrhage can complicate resection, sometimes limiting surgical intervention. Visual and endocrine symptoms dominate presentations; however, memory decline, seen in the present case, has been reported in at least one other case study.5 Extensive peritumoral edema may have contributed to our patient’s memory problems. No tumor cyst was observed in the present case. Growth rates for supratentorial hemangioblastomas are variable with poorly understood determinants.8 Clinical observations have suggested that pregnancy in VHL-positive patients may increase the rate of hemangioblastoma growth and development.2 Specifically, it has been suggested that pregnancy induces a proangiogenic state that promotes hemangioblastoma growth, involving the interaction between placental growth factor (PGF) and vascular endothelial growth factor receptor 1. An additional hypothesis is that the hemodynamic changes that occur during pregnancy, including increased venous pressure, vascular bed engorgement, and increased circulating blood volume, facilitate the growth of hemangioblastoma.9 However, other publications dispute this and have found no correlation between pregnancy and hemangioblastoma development in patients with VHL disease.3,10 The conflicting results in recent studies are possibly related to small case numbers. In the present case, no imaging prior to the presentation was available, and it is not known whether tumor was present at conception. Tumor shrinkage after delivery and radiotherapy was impressive in our case, and it is conceivable that changes in endocrine status, PGF levels, and hemodynamic environment may have contributed. Finally, GnRH agonism, present here during ovulation induction prior to pregnancy, has not been identified as a risk factor for hemangioblastoma growth; however, it has been implicated in the growth of meningioma.11,12 Gross-total resection of symptomatic lesions is generally considered the best management approach to hemangioblastoma. Radiation therapy (RT) in the form of SRS, SRT, and conventional fractionated external beam radiotherapy has been used in the management of hemangioblastoma, particularly for small, residual, or recurrent lesions. This treatment modality is an important consideration for cases in which complete tumor removal is not possible, as can be the case in the suprasellar region, where tumors often have intimate connections to vital anatomy. The treatment protocol used in the present case is consistent with previously published protocols for the treatment of hemangioblastoma deemed not amenable to focal single-fraction SRS,13 which can include those abutting the optic apparatus. For hemangioblastomas in all locations, at 5 years following RT, local control has been reported in 71%–88% of cases.14 Because of the limited data available in the literature, it is difficult to ascertain the rate of success following RT for hemangioblastomas in unusual locations, including suprasellar, as in this case. Three cases identified in the literature describe suprasellar hemangioblastomas in which total resection was not performed, and RT resulted in good outcomes for all 3 cases.4,15,16 In addition to the present case, these emphasize the utility of RT in the management of suprasellar hemangioblastomas. In the current case, we hypothesize that hormonal factors were a contributor to the marked reduction in the dimensions of the tumor 3 months post-RT. However, the further subsequent reduction seen at continued follow-up suggests an efficacious radiation effect, causing continued tumor shrinkage. Although not available at the time of treatment for this patient, belzutifan has since emerged as an efficacious pharmacological treatment for some VHL-associated hemangioblastomas.17 The patient in our case experienced significant visual improvement in the postoperative period, despite virtual blindness perioperatively. While visual improvement is commonly observed following resection of sellar and parasellar masses,18 rates of improvement appear to be lower in those treated with radiotherapy.19,20 In a retrospective cohort study of 79 patients with suprasellar tumors and preoperative blindness, Suri et al.21 observed an improvement to serviceable vision in 7 patients (8.9%). However, all patients in this series were treated with resection, and none were diagnosed with hemangioblastoma, unlike the present case. Still, certain documented predictors of favorable outcome were present in our case, including a short duration of symptoms and younger age at presentation.21 A recent review found that, of the 32 suprasellar hemangioblastoma cases for which information is available, only 5 (15.6%) were confirmed to have a cystic component, while the remaining 27 (84.4%) were solid with no tumor cyst.22 This contrasts with hemangioblastomas overall, in which only 40% have no cystic cavity.23 These observations suggest that suprasellar hemangioblastomas have characteristic gross morphological features, as supported by the present case, in which no tumor cyst was observed. Lessons The present case highlights the high vascularity and vital regional anatomy that complicates the surgical management of suprasellar hemangioblastoma. We observed a positive response in a 30-year-old pregnant woman who was managed with delivery followed by SRT. This case underscores the value of RT as a treatment option for suprasellar hemangioblastoma. The potential for hemangioblastoma growth in association with pregnancy should be considered for those harboring a hemangioblastoma. This is especially true for those with a personal or family history of VHL, in whom there can be occult lesions or stable lesions managed by serial imaging surveillance. Should a lesion grow to symptomatic proportions during pregnancy, delivery of the baby may represent a potential adjuvant therapeutic option, on the basis of tumor involution on interruption of pregnancy factors. Disclosures S. Yip reported being a member of the advisory board of Amge and personal fees from AstraZeneca, Bayer, Pfizer, Roche, and Servier outside the submitted work. Author Contributions Conception and design: McKenzie, Akagami, Gooderham. Acquisition of data: McKenzie, Shewchuk, Akagami, Yip. Analysis and interpretation of data: Toyota, McKenzie, Shewchuk, Akagami, Yip, Shutz. Drafting the article: Toyota, Shutz. Critically revising the article: Toyota, McKenzie, Shewchuk, Akagami, Gooderham. Reviewed submitted version of manuscript: Toyota, McKenzie, Shewchuk, Akagami, Gooderham, Yip. Approved the final version of the manuscript on behalf of all authors: Toyota. Administrative/technical/material support: Akagami, Yip. Study supervision: Akagami, Gooderham, Yip. Supplemental Information Previous Presentations Portions of this work were presented at the 2025 North American Skull Base Society Congress, New Orleans, LA, February 12–15, 2025. Correspondence Patrick Toyota: University of Saskatchewan, Saskatoon, SK, Canada. wvx186@usask.ca.